Idorsia Pharmaceuticals Ltd Overview
Pro stress-test →Idorsia is a Swiss biopharmaceutical company specializing in discovering, developing, and commercializing innovative small-molecule medicines for unmet medical needs in CNS, cardiovascular, immunological, and orphan disease areas. Spun out from Actelion following its 2017 acquisition by Johnson & Johnson, Idorsia operates from the Basel region and maintains a highly experienced drug development team.
Strategic Profile
Pro stress-test →The company is positioned as a specialized small-molecule drug discovery engine with a diversified portfolio including commercialized products (QUVIVIQ for insomnia, TRYVIO/JERAYGO for resistant hypertension) and multiple clinical-stage assets. Idorsia leverages strategic partnerships with major players including Janssen Biotech, Viatris, and Neurocrine Biosciences to maximize portfolio value and reduce development risk.
Competitive Landscape
Pro stress-test →Idorsia competes in the specialty pharmaceutical space against larger competitors including Galapagos, Neurocrine Biosciences, and other biotech firms developing CNS and cardiovascular therapies. The company differentiates through its focus on small-molecule drug discovery, European biotech hub positioning, and partnership-driven portfolio approach rather than full capitalization of development programs.
Industry Context
Idorsia Pharmaceuticals Ltd operates in Biopharmaceuticals/Small-Molecule Drug Development.
Key facts
Founded: 2017 · Headquarters: Allschwil, Switzerland · Employees: 552 · Revenue: $273M · Market cap: $1.17B